GlassScriptPhysician profile
Lionel E Desroches
NPI 1003928987
$10,771.41
in general payments reported to CMS, 2019-2025
40 companies · $1,718 in 2025
The $1,718 reported for 2025 was more than what 88% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,213 · 2020: $970 · 2021: $717 · 2022: $1,389 · 2023: $1,028 · 2024: $1,736 · 2025: $1,718.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,334 · Education: $148.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,333.85 |
| Education | $148.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Opko Pharmaceuticals, LLC | $1,839.67 | 2019-2025 | Rayaldee |
| Astrazeneca Pharmaceuticals LP | $1,595.92 | 2019-2025 | Farxiga, Lokelma, Airsupra |
| Aurinia Pharma U.S., INC. | $835.13 | 2021-2025 | Lupkynis |
| Vifor Pharma, INC. | $794.91 | 2019-2025 | Veltassa |
| Travere Therapeutics, INC. | $767.84 | 2023-2025 | Filspari |
| Boehringer Ingelheim Pharmaceuticals, INC. | $592.24 | 2019-2025 | Jardiance |
| Merck Sharp & Dohme LLC | $533.72 | 2019-2025 | Verquvo |
| Lilly USA, LLC | $482.23 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $464.05 | 2019-2025 | Ozempic, Rybelsus |
| Horizon Therapeutics Plc | $371.16 | 2019-2022 | |
| Amgen INC. | $366.76 | 2019-2024 | Tavneos, Parsabiv |
| Otsuka America Pharmaceutical, INC. | $236.45 | 2019-2024 | Jynarque |
| Bayer Healthcare Pharmaceuticals INC. | $221.40 | 2021-2024 | |
| Akebia Therapeutics INC | $193.74 | 2019-2022 | |
| Pfizer INC. | $161.95 | 2019-2025 |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lionel Desroches listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.